Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADH1A | P07327 | 1/20 | 0.40 |
| ▸ | KIT | P10721 | 1/20 | 0.40 |
| ▸ | FLT1 | P17948 | 1/20 | 0.40 |
| ▸ | FLT4 | P35916 | 1/20 | 0.40 |
| ▸ | KDR | P35968 | 1/20 | 0.40 |
| ▸ | ABL2 | P42684 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
| ▸ | BACE1 | P56817 | 1/20 | 0.39 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | CHRM3 | P20309 | 6/20 | 0.35 |
| ▸ | CASP1 | P29466 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6205071 | 1.00 | ADH1A (0.40) | ADH1AKITFLT1FLT4KDR | |
| SCHEMBL29723333 | 0.91 | BACE1 (0.41) | ADH1AKITFLT1FLT4KDR | |
| SCHEMBL18086012 | 0.91 | BACE1 (0.41) | ADH1AKITFLT1FLT4KDR | |
| SCHEMBL16942012 | 0.85 | ADH1A (0.41) | ADH1AKITFLT1FLT4KDR | |
| SCHEMBL21297107 | 0.83 | ADH1A (0.39) | ADH1AKITFLT1FLT4KDR | |
| SCHEMBL19607324 | 0.82 | EPHX2 (0.39) | ADH1AKITFLT1FLT4KDR | |
| SCHEMBL16847519 | 0.81 | ADH1A (0.48) | ADH1AKITFLT1FLT4KDR | |
| SCHEMBL16933070 | 0.81 | BACE1 (0.37) | ADH1AKITFLT1FLT4KDR | |
| SCHEMBL18064565 | 0.80 | ADH1A (0.38) | ADH1AKITFLT1FLT4KDR | |
| SCHEMBL18064566 | 0.80 | ADH1A (0.38) | ADH1AKITFLT1FLT4KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10391182-B2 | Bifunctional cytotoxic agents | PFIZER INC. (US) | 2019-08-27 | — | — | US | disclosed |
| US-20150209445-A1 | BIFUNCTIONAL CYTOTOXIC AGENTS | PFIZER INC. | 2015-07-30 | — | — | US | disclosed |
| US-20150209445-A1 | BIFUNCTIONAL CYTOTOXIC AGENTS | PFIZER INC. | 2015-07-30 | — | — | US | disclosed |
| WO-2015110935-A1 | BIFUNCTIONAL CYTOTOXIC AGENTS | PFIZER INC. (US) | 2015-07-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150209445-A1 | BIFUNCTIONAL CYTOTOXIC AGENTS | PAICS, CYTH3, CYTH2 | ADH1A 3759/4885KIT 2300/4885FLT1 3066/4885 |
| US-10391182-B2 | Bifunctional cytotoxic agents | PAICS, CYTH3, CYTH2 | ADH1A 3759/4885KIT 2300/4885FLT1 3066/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.